New drug combo shows promise for tough liver cancer
NCT ID NCT03519997
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times
Summary
This study tests a combination of two drugs, pembrolizumab and bavituximab, in 35 adults with advanced liver cancer that cannot be treated with surgery or local therapies. The goal is to see if the combination shrinks tumors and improves survival. Participants must not have had prior systemic therapy for their advanced cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Parkland Health & Hospital System
Dallas, Texas, 75235, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can an immunotherapy drug keep liver cancer at bay after surgery?